Nicotine Use In Mental Illness And Neurological Disorders

Nicotine Use in Mental Illness and Neurological Disorders, a volume in the International Review of Neurobiology series, is a comprehensive overview of the state-of-the-art research into nicotine use in mental illness and neurological disorders. It reviews current knowledge and understanding, also provides a starting point for researchers and practitioners entering the field. Provides a broad coverage of subject matter Presents a comprehensive overview of the state-of-the-art research into nicotine use in mental illness and neurological disorders Ideal for researchers and practitioners, and those just entering the field

Today, 25% of Americans smoke and 50% of smokers die from tobacco-related illnesses. Meanwhile, little attention has been given to implementing cessation therapies for our patients who smoke. Nicotine in Psychiatry: Psychopathology and Emerging Therapeutics examines this timely subject. The book's contributors, subject matter experts in the growing field of nicotine neurobiology andclinical pharmacology, cover the latest knowledge on The pharmacokinetics and pharmacodynamics of nicotine The effect of nicotinic receptors on the central nervous system (CNS), the recent advances made in understanding the normal function of these receptors, and how this knowledge transfers to the clinical treatment of many CNS disorders Behavioral factors influencing the effects of nicotine and nicotine's addictive capacity The association between smoking and specific mental disorders and the association between nicotine and mood Clinical applications of nicotine as a potential therapeutic agent for a variety of disorders, such as attention deficit, Alzheimer's and Parkinson's diseases, epilepsy, inflammatory bowel disease, schizophrenia, and Tourette's syndrome Nicotine replacement therapies and various smoking-cessation strategies This book makes fascinating reading for anyone interested in the recent tobacco public policy debates, as well as clinicians and researchers looking for current information on nicotine and its clinical applications.

Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases: Epidemiological Data on Smoking and Preclinical and Clinical Data on Nicotine provides a comprehensive summary of the epidemiological data on smoking and several neurological disorders, including Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Tourette’s syndrome, schizophrenia, anxiety, depression and ADHD, as well as preclinical and clinical data on the effects of nicotine. Despite the obvious and undisputed harmful nature of smoking, evidence suggests that some tobacco and tobacco smoke-derived constituents may offer neuroprotective effects, possibly in combinations, rather than individually. This unprecedented book describes the complex relationships between smoking and neurological disease and the bioactive compounds found in tobacco. It provides a comprehensive review of nicotine and other compounds found in tobacco plant, with scientific evidence of neuroprotective and anti-inflammatory effects that may act in conjunction with nicotine to exert neuroprotective effects observed in smokers. By presenting findings beyond harmful cigarette smoke effects, attention can be drawn to individual compounds of tobacco that may serve as inspiration for further therapy development. Presents the first comprehensive, tabulated summary of literature on the epidemiological data on smoking and neurological disease Includes preclinical and clinical data on nicotine in neurological diseases and mechanisms of action of nicotine in neuroprotection Features a comprehensive summary of non-nicotine smoke constituents with potentially neuroprotective and anti-inflammatory properties Discusses Multiple Sclerosis, Alzheimer’s disease, Parkinson’s Disease, Schizophrenia, Depression, ADHD, Anxiety and Tourette’s Syndrome in the context of smoking and nicotine

Negative Affective States and Cognitive Impairments in Nicotine Dependence is the only book of its kind that addresses nicotine use and abuse in the context of negative reinforcement mechanisms. Written and edited by leading investigators in addiction, affective, genetic, and cognitive research, it provides researchers and advanced students with an overview of the clinical bases of these effects, allowing them to fully understand the various underlying dysfunctions that drive nicotine use in different individuals. In addition, this book examines animal models that researchers have utilized to investigate the biological bases of these dysfunctions. The combination of clinical and preclinical approaches to understanding nicotine dependence makes this book an invaluable resource for researchers and practitioners seeking to develop targeted treatments aimed at ameliorating symptoms of nicotine dependence, as well as identifying premorbid differences in affective or cognitive function. Provides a unique perspective on nicotine dependence that emphasizes negative reinforcement rather than positive reinforcement Examines psychiatric comorbidities and alleviation of withdrawal states as motivation for continued tobacco use Includes both clinical and preclinical perspectives Includes genetic and multi-neurotransmitter perspectives on nicotine use and withdrawal Emphasizes heterogeneity of underlying reasons for smoking, the need for multiple animal models to understand this heterogeneity, and the expectation of heterogeneous responses to potential treatments, underscoring the need for personalized therapeutics

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.

Smoking causes and contributes to a large number of human diseases, yet due to the large number of potentially hazardous compounds in cigarette smoke -- almost 5,000 chemicals have been identified, establishing the link between smoking and disease has often proved difficult. This unbiased and scientifically accurate overview of current knowledge begins with an overview of the chemical constituents in cigarette smoke, their fate in the human body, and their documented toxic effects on various cells and tissues. Recent results detailing the many ways components of cigarette smoke adversely affect human health are also presented, highlighting the role of smoking in cardiovascular, respiratory, infectious and other diseases. A final chapter discusses current strategies for the treatment and prevention of smoking-induced illness. Despite the obvious importance of the topic, this is the first comprehensive reference on tobacco smoke toxicity, making for essential reading for all toxicologists and healthcare professionals dealing with smoking-related diseases.

The primary purpose of this book and its companion volume The Behavioral Genetics of Nicotine and Tobacco is to explore the ways in which recent studies on nicotine and its role in tobacco addiction have opened our eyes to the psychopharmacological properties of this unique and fascinating drug. While The Behavioral Genetics of Nicotine and Tobacco considers the molecular and genetic factors which influence behavioral responses to nicotine and how these may impact on the role of nicotine in tobacco dependence, the present book focuses on the complex neural and psychological mechanisms that mediate nicotine dependence in experimental animal models and their relationship to tobacco addiction in humans. These volumes will provide readers a contemporary overview of current research on nicotine psychopharmacology and its role in tobacco dependence from leaders in this field of researchand will hopefully prove valuable to those who are developing their own research programmes in this important topic.